Details of the Drug

General Information of Drug (ID: DMLIPY1)

Drug Name
Xmab 5871
Synonyms XmAb 5871 (TN)
Indication
Disease Entry ICD 11 Status REF
Autoimmune diabetes 5A10 Phase 2 [1]
IgG4 related disease 4A43.0 Phase 2 [2]
Systemic lupus erythematosus 4A40.0 Phase 2 [2]
Rheumatoid arthritis FA20 Phase 1/2 [3]
Cross-matching ID
TTD ID
D00NXT
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN Modulator [4]
Immunoglobulin gamma Fc receptor IIB (FCGR2B) TT5RWKQ FCG2B_HUMAN Modulator [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Autoimmune diabetes
ICD Disease Classification 5A10
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B-lymphocyte surface antigen B4 (CD19) DTT CD19 2.33E-24 -1.06 -1.33
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035125)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT02867098) XmAb5871 Bioavailability Study
4 Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fc receptor IIb inhibitory receptor.Arthritis Rheumatol.2014 May;66(5):1153-64.
5 CD19 as an attractive target for antibody-based therapy. MAbs. 2012 Sep-Oct;4(5):571-7.